Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies by Baraliakos, X, Ranza, R, Östör, A, Ciccia, F, Coates, LC, Rednic, S, Walsh, JA, Douglas, K, Gao, T, Kato, K, Song, I-H, Ganz, F, Deodhar, A

International league of associations for rheumatology recommendations for the management of psoriatic arthritis in resource-poor settings by Elmamoun, M, Eraso, M, Anderson, M, Maharaj, A, Coates, L, Chandran, V, Abogamal, A, Adebajo, AO, Ajibade, A, Ayanlowo, O, Azevedo, V, Bautista-Molano, W, Carneiro, S, Goldenstein-Schainberg, C, Hernandez-Velasco, F, Ima-Edomwonyi, U, Lima, A, Medina-Rosas, J, Mody, GM, Narang, T, Ortega-Loayza, AG, Ranza, R, Sharma, A, Toloza, S, Vega-Espinoza, L, Vega-Hinojosa, O